Expansion potential The company has recently completed the acquisition of NIRLAB and launched new MX908 capabilities, indicating aggressive product expansion and integration opportunities that can be cross-sold to existing customers in bioprocessing, pharma, forensics, and life sciences research.

High-value clients With a focus on point-of-need chemical analysis and applications in life sciences, bioprocessing, pharma/biopharma, and hazardous environments, target customers include high-stakes labs, customs, and hazardous response teams that require rapid, actionable results.

Strategic partnerships Recent M&A activity and investor-facing engagements suggest a path to channel partnerships and system integrator collaborations, offering co-sell opportunities around NX/trace detection, VipIR capabilities, and integrated analytical workflows.

Integrated tech stack Leveraging devices that combine microfluidics, software automation, and ML, there is opportunity to upsell advanced software licenses, data analytics, and maintenance packages to current MX908 and VipIR users, as well as potential integration with customers’ LIMS workflows.

Market traction signals Recent quarterly revenue beats and active investor events, along with a clear track record of product announcements (trace chemical ID, fentanyl classifier, VipIR) indicate momentum that sales teams can leverage to engage prospects with case studies, ROI narratives, and mission-critical use cases.